Literature DB >> 10840013

Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation.

H Nakashima1, K Kumagai, H Urata, N Gondo, M Ideishi, K Arakawa.   

Abstract

BACKGROUND: The blockade of angiotensin II (Ang II) formation has protective effects on cardiovascular tissue; however, the role of Ang II in atrial electrical remodeling is unknown. The purpose of this study was to investigate the effects of candesartan and captopril on atrial electrical remodeling. METHODS AND
RESULTS: In 24 dogs, the atrial effective refractory period (AERP) was measured before, during, and after rapid atrial pacing. Rapid atrial pacing at 800 bpm was maintained for 180 minutes. The infusion of saline (n=8), candesartan (n=5), captopril (n=6), or Ang II (n=5) was initiated 30 minutes before rapid pacing and continued throughout the study. In the saline group, AERP was significantly shortened during rapid atrial pacing (from 149+/-11 to 132+/-16 ms, P<0.01). There was no significant difference in AERP shortening between the saline group and the Ang II group. However, in the candesartan and captopril groups, shortening of the AERP after rapid pacing was completely inhibited (from 142+/-9 to 147+/-12 ms with candesartan, from 153+/-15 to 153+/-14 ms with captopril, P=NS). Although rate adaptation of the AERP was lost in the saline group, this phenomenon was preserved in the candesartan and captopril groups.
CONCLUSIONS: The inhibition of endogenous Ang II prevented AERP shortening during rapid atrial pacing. These results indicate for the first time that Ang II may be involved in the mechanism of atrial electrical remodeling and that the blockade of Ang II may lead to the better therapeutic management of human atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10840013     DOI: 10.1161/01.cir.101.22.2612

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  93 in total

Review 1.  Mechanisms underlying the development of atrial arrhythmias in heart failure.

Authors:  Vias Markides; Nicholas S Peters
Journal:  Heart Fail Rev       Date:  2002-07       Impact factor: 4.214

Review 2.  Atrial fibrillation: basic mechanisms, remodeling and triggers.

Authors:  Akiko Shiroshita-Takeshita; Bianca J J M Brundel; Stanley Nattel
Journal:  J Interv Card Electrophysiol       Date:  2005-09       Impact factor: 1.900

Review 3.  [Atrial fibrillation].

Authors:  M G Hennersdorf; B E Strauer
Journal:  Internist (Berl)       Date:  2006-10       Impact factor: 0.743

Review 4.  Renal denervation for arrhythmias: hope or hype?

Authors:  Jonathan S Steinberg; Evgeny Pokushalov; Suneet Mittal
Journal:  Curr Cardiol Rep       Date:  2013-09       Impact factor: 2.931

5.  The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: data from the Heart and Soul Study.

Authors:  Christine C Welles; Mary A Whooley; Beeya Na; Peter Ganz; Nelson B Schiller; Mintu P Turakhia
Journal:  Am Heart J       Date:  2011-08-09       Impact factor: 4.749

Review 6.  Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies.

Authors:  Mark A Crandall; David J Bradley; Douglas L Packer; Samuel J Asirvatham
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

7.  Oxidative stress-mediated effects of angiotensin II in the cardiovascular system.

Authors:  Hairuo Wen; Judith K Gwathmey; Lai-Hua Xie
Journal:  World J Hypertens       Date:  2012-08-23

Review 8.  Angiotensin II and angiotensin 1-7: which is their role in atrial fibrillation?

Authors:  Annamaria Mascolo; Konrad Urbanek; Antonella De Angelis; Maurizio Sessa; Cristina Scavone; Liberato Berrino; Giuseppe Massimo Claudio Rosano; Annalisa Capuano; Francesco Rossi
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

9.  The effect of different treatment strategies on left atrial size in patients with lone paroxysmal atrial fibrillation-a prospective cohort study.

Authors:  Zengzhang Liu; Zhiyu Ling; Li Su; Jinjin Wu; Xianbin Lan; Yunqing Chen; Huaan Du; Qiang She; Yuehui Yin
Journal:  J Interv Card Electrophysiol       Date:  2008-09-23       Impact factor: 1.900

10.  Possible beneficial effect of olmesartan medoxomil on left atrial function in patients with hypertension : noninvasive assessment by acoustic quantification.

Authors:  Hui-Ping Gong; Wei Zhang; Li Li; Hong-Wei Tan; Zhi-Yong Ma; Xue-Zhen Zhong; Zhi-Hao Wang; Tao Song; Yun Zhang; Ming Zhong
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.